RITA Foundation Houston | Targeted Cancer Therapy

December 27, 2021 RITA Foundation announces support for newly authorized investigational trial to treat patients with metastatic Castration Resistant Prostate Cancer. RITA Foundation of Houston announces support for newly authorized investigational trial to treat patients with metastatic Castration Resistant Prostate cancer (mCRPC). Actinium (Ac)225-PSMA is a new and innovative Targeted Alpha Therapy (TAT) that is used under FDA authorized Investigational New Drug (IND) application. This clinical trial is currently conducted at Excel Diagnostics and Nuclear Oncology Center in Houston. Metastatic CRPC is one of the most aggressive form of prostate cancer and patients have limited therapeutic options. While there are about 2.2 million men in the united States living with prostate cancer, about 43,000 men suffer from this terminal condition. Prostate cancer is the 2nd most common cause of cancer death in men, in the united States. We are hopeful that our support will bring new and effective treatments for this catastrophic illness

Get in Touch Contacts • Address • Inquiries

9701 Richmond Avenue, Suite 120
Houston, TX 77042
SHOW MAP

Call: 713-781-6200
Fax: 713-781-6206
Email: Info@RITAFoundationHouston.org